Ebola Scare Creates New Application of PSID Tech Stock up 27% Early

Recommended Stock Newsletters
#1. PennyStockWarfare
#2. Nova Stocks
#3. Penny Stock Finder

SmallCapVoice Newsletter

Ebola Scare Creates New Application of PSID Tech Stock up 27% Early —————————————————————– Hot Stock to Watch —————————————————————– Company: PositiveID Corporation (OTCQB: PSID) Last:

Price: 0.069 Change (%): + 0.015 (27.78) Volume: 2,630,393 http://app.getresponse.com/click.htmlx=a62b&lc=Qrxwp&mc=BT&s=V2HFR&u=BEqW&y=G& Ebola Outbreak Escalates Urgency and Spikes Visibility for Emerging Contender in Biothreat Detection — PositiveID Corp.

Investor Update by SmallCapTraders.com NEW YORK, Aug. 7, 2014 /PRNewswire/ – PositiveID Corp. (OTCQB:

PSID), with offices in Delray Beach, FL and Pleasanton, CA, is an emerging player in the biothreat detection market. The recent high visibility Ebola outbreak has created significant alarm among government officials as well as industry experts with a steady stream of media coverage flowing out over the last several days as the public follows the story closely. A number of industry experts and potential contenders in the market for diagnostic testing products have surfaced with various opinions and potential solutions with varying degrees of applicability to the near term problem at hand; preventing uncontrolled spread of Ebola (and other bio-threats) that could result in a pandemic or other major public health crisis.

PSID has a potentially game changing disruptive technology without any apparent current competition. Currently state of the art Ebola tests use polymerase chain reaction (PCR) a molecular diagnostic technology used to amplify a single or a few copies of a piece of DNA across several orders of magnitude. Expedited test results currently must be sent to a lab and take about 8 hours to turn around. PSID Firefly handheld technology may be able to produce valid test results on site eliminating the need to send samples to a lab and simultaneously reduce the total time for a result to 30 minutes. Reductions in testing time of that magnitude combined with eliminating the need to send samples to a lab would be truly revolutionary.

Continue Reading – http://app.getresponse.com/click.htmlx=a62b&lc=QrxQW&mc=BT&s=V2HFR&u=BEqW&y=x& —————————————————————– IMPORTANT DISCLAIMER – PLEASE READ THOROUGHLY —————————————————————– SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security.

SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com.

opt out of our distribution list at any time by clicking on the “

This entry was posted in SmallCapVoice and tagged . Bookmark the permalink.

Comments are closed.